Shattuck Reports Q4 Revenue of $0, Cash Approximately $78.1M
Reports Q4 revenue $0, consensus $166,670. As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M, as compared to $73.0M as of December 31, 2024. "SL-325 is now the first DR3 blocking antibody to generate human clinical data, and we are very pleased with the progress we have made in our Phase 1 clinical trial, which is nearly complete. We look forward to sharing the data from this trial in the second quarter, and anticipate initiating our Phase 2 clinical trial in Crohn's disease in the third quarter," said Taylor Schreiber, CEO of Shattuck.
